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Cardiovascular disease (CVD) is the most prevalent cause of mortality among patients with
type 1 or type 2 diabetes, due to accelerated atherosclerosis. Recent evidence suggests a
strong link between atherosclerosis and insulin resistance, due to impaired insulin recep-
tor (IR) signalling. Here, we demonstrate that inhibiting the activity of protein tyrosine phos-
phatase 1B (PTP1B), themajor negative regulator of the IR prevents and reverses atheroscle-
rotic plaque formation in an LDLR−/− mouse model of atherosclerosis. Acute (single dose)
or chronic PTP1B inhibitor (trodusquemine) treatment of LDLR−/− mice decreased weight
gain and adiposity, improved glucose homeostasis and attenuated atherosclerotic plaque
formation. This was accompanied by a reduction in both, circulating total cholesterol and
triglycerides, a decrease in aortic monocyte chemoattractant protein-1 (MCP-1) expression
levels and hyperphosphorylation of aortic Akt/PKB and AMPKα. Our findings are the first to
demonstrate that PTP1B inhibitors could be used in prevention and reversal of atheroscle-
rosis development and reduction in CVD risk.
Introduction
Cardiovascular disease (CVD) is a general term used to describe all the conditions affecting the heart
and blood vessels and is responsible for almost a third of deaths worldwide (WHO Statistics, http:
//www.who.int/mediacentre/factsheets/fs317/en/). Many conditions that contribute to CVDs are due to
narrowing and hardening of the blood vessels through a process known as atherosclerosis, arising due to
lipid accumulation which, over time, develops into plaques. Subsequently, these atherosclerotic plaques
can lead to ischaemic injury by a number of mechanisms such as complete occlusion of the blood vessel or
alternatively, the plaquemay become unstable and rupture resulting in thrombosis [1,2]. This processmay
be exacerbated by risk factors encompassing genetic aspects, lifestyle choices such as smoking, excessive
drinking, physical inactivity and obesity or conditions such as diabetes [3]. Indeed, in both type 1 and
type 2 diabetic patients, a high proportion of mortality is associated with CVD, where defective insulin
signalling leads to endothelial dysfunction and accelerated atherosclerosis. The mechanism contributing
to this pathology is somewhat unclear; however, it has been suggested that insulin resistance and hy-
perglycaemia results in intracellular metabolic changes leading to oxidative stress and chronic low-grade
inflammation [4]. Therefore, clarification of the mechanism controlling these diseases is needed to enable
the design of more targeted and effective therapeutics.
In support of a link between defective insulin receptor (IR) signalling and atherogenesis, it was found
that apolipoprotein-E-deficient mice (ApoE−/−) devoid of IR in the vascular endothelium had increased
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plaque development [5]. Moreover, ApoE−/− mice with a heterozygous deletion of the IR and its downstream target,
IR substrate 1 (IRS1), also develop accelerated atherosclerosis [6], as well as the mice lacking IR substrate 2 (IRS2−/−)
[7]. Furthermore, decreased insulin signalling in nonhaematopoietic cells, as achieved by transplantation of ApoE−/−
mouse model of atherosclerosis with bone marrow cells from IRS1+/− IR+/− ApoE−/− mice, contributed to increased
atherogenesis in these mice [6]. Finally, mice that were devoid of both LDLR−/− and Akt2, an important downstream
component of the IR signalling cascade, exhibited impaired glucose homoeostasis, elevated insulin and cholesterol
levels and developed more complex atherosclerotic plaques [8]. Therefore, targeting components that inhibit IR sig-
nalling could prove to be an effective therapeutic.
Protein tyrosine phosphatase (PTP)1B (PTP1B) has been identified as the major negative regulator of the IR
itself [9]. In mice, whole body PTP1B−/− studies established PTP1B as a major regulator of insulin sensitivity
and body mass, via inhibition of insulin and leptin signalling respectively [10,11]. Our recent data suggested that
hepatic-specific deletion of PTP1B, in addition to improving glucose and lipid homoeostasis and increasing insulin
sensitivity, was protective against endothelial dysfunction in response to high fat diet (HFD) [12]. This was also as-
sociated with decreased hepatic inflammation in these mice [13]. Specifically, mice lacking hepatic PTP1B exhibited
decreased systolic and diastolic blood pressure, in response to HFD feeding, when compared with control littermates
[12]. Furthermore, we have also shown that myeloid-specific PTP1B deletion can protect against HFD-induced in-
flammation and hyperinsulinaemia and is facilitated by an increase in the secretion of the anti-inflammatory cytokine
interleukin (IL)-10 (IL-10) and a decrease in pro-inflammatory TNFα cytokine secretion [14]. Since atherosclero-
sis is regarded as a chronic low level inflammatory disease [15-18], we hypothesized that targeting PTP1B activity
using a PTP1B-specific inhibitor trodusquemine [19], could prove effective in prevention and possibly reversal of
atherosclerotic plaque formation. This would enable direct testing of the translational potential of PTP1B inhibitors
[20], which are in phase II clinical trials for diabetes treatment, and phase I clinical trials for breast cancer treatment
(https://clinicaltrials.gov/ct2/show/NCT02524951), as treatments for atherosclerosis and reduction in CVD risk. To
directly test this, we used the LDLR−/− mouse model of atherosclerosis, under physiological and obesogenic condi-
tions.
Methods
Animal studies
All animal procedures were performed under a project license approved by the U.K. Home Office under the Animals
(Scientific Procedures) Act 1986 (PPL 60/3951). Eight weeks old male LDLR−/− mice were purchased from Jackson
Labs, individually housed and maintained at 22–24◦C on 12-h light/dark cycle with free access to food/water. Fol-
lowing 2 weeks of acclimatization time, mice were placed on chow or HFD (42% from fat, 0.2% cholesterol, Envigo,
Huntingdon, U.K.) for 12 weeks and weighed weekly to monitor weight gain.
Drug treatments
The PTP1B inhibitor trodusquemine was obtained from Dr N. Tonks (Cold Spring Harbor, U.S.A.). After 1 week on
HFD, 20 mice were injected intraperitoneally (I.P.) with the PTP1B inhibitor trodusquemine (10 mg/kg), followed
by four subsequent weekly injections of 5 mg/kg, as previously described for ob/ob mice [19] and a 6-week washout
period. These were designated as the chronic group, whereas the remaining mice were injected with saline. After 8
weeks on HFD, a further 20 mice were injected with a single dose of 10 mg/kg trodusquemine and designated accord-
ingly, followed by a 4-week washout period. At week 12 on HFD, mice were fasted for 5 h and injected with either
saline or insulin (10 mU/g body weight) for 10 min prior to culling by CO2 inhalation and subsequent cervical dislo-
cation. Trodusquemine treatment was halted prior to the end of the study to ensure that the procedure of treatment
(by intraperitoneal injection) did not affect the terminal signalling experiment by altering stress hormone levels and
thus adversely affecting insulin signalling. Heart and aortic tissues were harvested and collected for further analysis.
Tissues for subsequent Western blotting or qPCR analysis were frozen in liquid nitrogen and stored at –80◦C until
needed, whereas tissues for histology were immersed in formalin for 24 h at 4◦C, then stored at 4◦C in PBS until
analysed.
Glucose tolerance tests
Mice were fasted for 5 h prior to commencement of glucose tolerance tests (GTTs). Briefly, baseline glucose lev-
els were sampled from tail blood using glucose meters (AlphaTRAK, Abbott Laboratories, Abbott Park, IL, U.S.A.).
Subsequently mice were injected I.P. with 20% glucose (w/v) and blood glucose measured at 15, 30, 60 and 90 min
post-injection.
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Body fat mass composition
The body composition of eachmouse was analysed using an EchoMRI-3-in-1 scanner (EchoMedical Systems,Hous-
ton, TX, U.S.A.).
Immunoblotting
Frozen aorta tissues were homogenized in 300 μl of ice-cold radioimmunoprecipitation assay (RIPA) buffer (10 mM
Tris/HClpH 7.4, 150mMNaCl, 5mMEDTApH 8.0, 1mMNaF, 0.1% SDS, 1%TritonX-100, 1% sodiumdeoxycholate
with freshly added 1mMNaVO4 and protease inhibitors) using a PowerGen 125 homogenizer and lysates normalized
to 1 μg per 1 μl. Proteins were separated on a 4–12% bis-tris gel by SDS/PAGE and transferred on to nitrocellulose
membrane. Membranes were probed for the following targets; p-IR (Tyr1162/1163), IR β-chain, p-AKT (Ser473), p-p38
(The181/Tyr182), total p-38, p-S6 (Ser235/236), total S6, p-AMPKα (Thr172), total AMPKα, PTP1B and GAPDH.
RNA extraction and qPCR
Frozen tissues were lysed in TRIzol reagent (Sigma, U.K.) and RNA isolated using phenol/chloroform extraction ac-
cording to manufacturer’s instructions. RNA was then synthesized into cDNA using tetrokits (Bioline) and subjected
to qPCR analysis using SYBR and LightCycler 480 (Roche). Gene expression of intracellular cell adhesionmolecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1) was
determined relative to the reference gene ELF1.
Histology
Immediately following cervical dislocation, hearts were immersed in formalin and stored at 4◦C for 24 h, before
being transferred to PBS until further analysis. Hearts were bisected to remove the lower ventricles, frozen in OCT
and subsequently sectioned at 5-μm intervals until the aortic sinus was reached. Sections were mounted and stained
with Oil Red O to assess plaque formation. Images were captured using a light microscope and plaque formation
quantified using ImageJ software.
Serum analysis
Blood was collected during terminal procedures after fasting (5 h) and spun at 5000×g to isolate serum, then stored
at –80◦C. Serum samples were subsequently analysed for insulin using ELISA (R&D Systems) or total cholesterol and
triglycerides (Sigma).
Statistical analysis
We expressed all the values as mean +− S.E.M. We determined group sizes by performing a power calculation to
lead to 80% chance of detecting a significant difference (P≤0.05). For both in vivo and ex vivo data, each n value
corresponds to a single mouse. Statistical analyses were performed by using one- or two-way ANOVA, followed by
Tukey’s or Dunnett’s multiple-comparison tests to compare the means of three or more groups or by an unpaired
two-tailed Student’s t test to compare the means of two groups. Variances were similar between groups. In all the
figures, */#P≤0.05, **/##P≤0.01, ***/###P≤0.001, ****P≤0.0001. All analyses was performed using GraphPad Prism
(GraphPad Software).
Results
PTP1B inhibitor treatment decreases body weight and improves global
glucose homeostasis
The exponential rise in patients presenting with obesity and type 2 diabetes has resulted in an increased interest from
pharmaceutical companies for the use of PTP1B inhibitors as potential therapeutics [20]. Given there is increasing
evidence implicating defective insulin signalling as a major contributor to the pathogenesis of atherosclerosis, we
hypothesized that PTP1B inhibition should have beneficial protective effects. To determine if global PTP1B inhibitors
would attenuate plaque formation, we used the LDLR−/− mouse model of atherosclerosis [21]. We assessed whether
a single dose and/or chronic PTP1B inhibition could slow or reverse atherosclerotic plaque formation in mice fed
on HFD (or chow as control). The PTP1B inhibitor trodusquemine was selected as this drug has been reported to
be more specific than previously synthesized compounds, since it binds and inhibits allosterically rather than at the
catalytic domain which is highly conserved between other tyrosine phosphatase family members [22]. Furthermore,
this drug is currently in phase I trials in breast cancer patients (https://clinicaltrials.gov/ct2/show/NCT02524951),
after previously being tested as a treatment for type 2 diabetes and obesity.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY).
2491
Clinical Science (2017) 131 2489–2501
DOI: 10.1042/CS20171066
0 2 4 6 8 10 12
HFD
12 WEEKS BLOOD AND 
TISSUE COLLECTION
0 2 4 6 8 10 12
CHOW
ECHO MRI ECHO MRI ECHO MRI
GTT GTT GTT
INHIBITOR OR SALINE
(CHRONIC)
INHIBITOR OR SALINE
(SINGLE DOSE)A.
B. C.
HFD
DAY
W
ei
gh
t (
g)
0 10 20 30 40 50 60 70 80
15
20
25
30
35
40 saline
single dose
chronic
**** ******************** ****
************
****************
CHOW
DAY
W
ei
gh
t (
g)
0 10 20 30 40 50 60 70 80
15
20
25
30
35 saline
single dose
chronic
****************************
****
*
Figure 1. Global PTP1B inhibition leads to reduced body weight
(A) Schematic representation of the experimental design. LDLR−/− male mice were divided into HFD-fed and chow-fed saline-treated,
single-dose trodusquemine (10 mg/kg I.P. at week 8) and chronic trodusquemine (a single 10 mg/kg I.P. followed by four weekly injections
at 5 mg/kg). (B,C) Weights of mice during the course of the experiment-fed HFD (B, n=24 per group) or chow (C, n=4 per group). Data are
represented as mean +− S.E.M. and analysed by two-way ANOVA followed by Bonferonni multiple comparison t tests where *P≤0.05, or
****P≤0.0001 when compared with saline-treated control mice.
Mice were treated chronically with trodusquemine or given a single dose after 8 weeks of HFD feeding (Figure
1A). Similar to whole-body PTP1B deletion [10] and treatment of ob/ob mice using these inhibitors [19], chronic
global inhibition of PTP1B prevented weight gain in both, chow and HFD-fed mice, when compared with saline
controls (Figure 1B,C), and led to decreased fat mass (Figure 2A,B). Lean mass was significantly decreased after 6
weeks of treatment in chronically treated mice (Figure 2C,D), when compared with vehicle controls, but remained
stable over 8–10 weeks, with no significant reduction in muscle mass when compared with vehicle-treated animals.
Following 8 weeks on HFD, a single dose of trodusquemine led to a 20% reduction in body weight (Figure 1B), with
greater than 50% reduction in fat mass, that accounted for the majority of the effect in weight loss (Figure 2A). In
addition, in agreement to what has been previously shown [19], trodusquemine exposure led to reduced food intake
in both HFD-fed and CHOW-fed cohorts (Supplementary Figure S1A,B). This was evidenced at week 9 which was
1 week following commencement of the single dose cohort. Interestingly, even though the chronic group had ceased
drug treatment after week 6, a significant reduction in food intake was still present. However, PTP1B activity assays
performed on liver tissues collected at week 12 during terminal culls revealed no significant inhibition of PTP1B
remained in drug treated cohorts (Supplementary Figure S1C). The lack of inhibition observed is likely to be due to
drugwashout, since single dose and chronic cohorts had 4 and 6weeks respectively, in the absence of inhibitor prior to
culling. Finally, in both, chronic and single dose inhibitor treatedmice, there was also a significantly improved glucose
handling in HFD-fed mice at all time points (weeks 8, 10 and 12 (Figure 3A,C,E respectively) whereas, although
improved in chow-fed mice at week 8 and 10 (Figure 3B,D), this was not evident at week 12 (Figure 3F).
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Figure 2. Global PTP1B inhibition leads to reduced adiposity
(A–D) Body composition was analysed using an Echo MRI 3-in-1 scanner where total body fat (A,B) and lean mass (C,D) were determined
(HFD, n=9–11 per group; chow, n=4 per group). Data are represented as mean +− S.E.M. and analysed by two-way ANOVA followed by
Bonferonni multiple comparison t tests where *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001 when compared with saline treated control
mice or #P≤0.05, ####P≤0.0001 when single dose and chronic groups were compared with each other.
Previous research has shown that HFD-fed mice develop hyperinsulinaemia [23,24]. In agreement with these stud-
ies, HFD led to an increase in circulating insulin levels in saline treated mice (Figure 4A), whereas, a significant
decrease in circulating insulin levels was observed in HFD-fed, but not in chow-fed mice, treated either with a sin-
gle dose or chronically with trodusquemine (Figure 4A,B respectively). Therefore, global inhibition of PTP1B, using
PTP1B specific inhibitor, mirrored results previously observed in whole-body PTP1B knockout mice, with regards
to beneficial effects on body weight, adiposity and glucose homoeostasis maintenance [10,11].
PTP1B inhibitor treatment protects against and reverses obesity-induced
increase in atherosclerotic plaque area
Increased blood lipid and lipoproteins are widely used as biomarkers to predict CVD risk [25]. To assess the lipid
lowering potential of PTP1B inhibition, lipid analyses were performed. A single dose and chronic treatment with
trodusquemine resulted in significantly decreased serum cholesterol (Figure 5A) and triglyceride levels (Figure 5B)
in HFD mice. A similar decrease was also measured in chow-fed trodusquemine-treated mice (Figure 5A,B). Subse-
quently, both single dose and chronic trodusquemine treatment resulted in attenuated plaque formation, as indicated
by a decrease in total plaque area (Figure 5C,D). Therefore, we show, for the first time, that use of global PTP1B
inhibitor not only decreases weight gain and improves glucose maintenance, but also decreases and most impor-
tantly reverses atherosclerotic plaque formation in an LDLR−/− mouse model of atherosclerosis, under obesogenic
HFD-feeding conditions.
Atherosclerosis is now widely regarded as a chronic, low-grade inflammatory condition characterized by an in-
creasedpro-inflammatory environment and decreased anti-inflammation, pro-resolutionary signalling [26,27]. Thus,
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Figure 3. Global PTP1B inhibition improves glucose maintenance
GTTs of saline, single dose and chronic drug treated mice fed on HFD (A,C,E) or chow (B,D,F) diets at week 8, 10 and 12. Mice were fasted
for 5 h prior to basal glucose monitoring (as described in Methods section) and subsequently mice were injected I.P. with 20% glucose
(w/v), and blood re-analysed at 15, 30, 60 and 90 min post-injection (HFD, n=8 per group; chow, n=4 per group). Data are represented as
mean +− S.E.M. and analysed by two-way ANOVA followed by Bonferonni multiple comparison t tests where *P≤0.05, **P≤0.01, ***P≤0.001,
****P≤0.0001 when compared with saline treated control mice or ##P≤0.01 when single dose and chronic groups were compared with each
other.
a vicious cycle ensues and a failure of the tissue to return to homeostasis. Therefore, we investigated the expression
of genes important in the inflammatory response including MCP-1, ICAM-1 and VCAM-1. MCP-1 is responsible
for recruiting monocytes to the aortic tissue whereas both ICAM-1 and VCAM-1 enable their transmigration [7].
Although there were no changes in the expression of aortic ICAM-1 (Figure 6A) or VCAM-1 (Figure 6B), in either
chronic or saline treated mice, those animals treated with a single injection of trodusquemine exhibited attenuated
aortic MCP-1 expression levels (Figure 6C). Hence, suggesting less monocyte recruitment and a reduced inflamma-
tory environment which could contribute to the reduction in plaque development.
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Figure 4. Global PTP1B inhibition reduces circulating insulin levels in HFD-fed mice
(A,B) Serum from blood collected at terminal culls was analysed for circulating insulin levels in HFD-fed (A) and chow-fed (B) mice using
ELISA (Millipore). Data are represented as mean +− S.E.M. and analysed by unpaired t tests where ***P≤0.001 when compared with saline
treated control mice.
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Figure 5. Global PTP1B inhibition reduces serum total cholesterol and triglycerides and prevents atherosclerotic plaque
development
Blood was collected at terminal culls and serum analysed for circulating total cholesterol (A) triglyceride levels (B) using ELISA (Sigma). (C)
Representative (n=5–6 per group) aortic root sections of HFD-fed mice stained with Oil Red O. (D) Quantification of plaque area as analysed
using ImageJ software. Data are represented as mean +− S.E.M. and analysed by unpaired two-tailed t tests where *P≤0.05 or **P≤0.01
when compared with saline control.
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Figure 6. Single-dose global PTP1B inhibition reduces MCP-1 expression
(A–C) Genetic analysis of aortic tissues (n=6 per group) as analysed by qPCR using using SYBR and Light Cycler 480 (Roche). Gene
expression of ICAM-1, VCAM-1 and MCP-1 was determined relative to the reference gene ELF1. Data are represented as mean +− S.E.M.
and analysed by unpaired two-tailed t tests where *P≤0.05 when compared with saline control.
Decrease in atherosclerotic plaque area with PTP1B inhibitor treatment
is accompanied by hyperphosphorylation of aortic Akt and AMPKα1
Given the decrease in serum lipids and aortic plaque formation in trodusquemine-treated mice, we hypothesized
that an up-regulation of IR signalling and associated downstream pathways could account for the beneficial effects
of PTP1B inhibitors in our study. However, in contrast with our hypothesis, there was no significant increase in
the aortic IR phosphorylation in either of our drug-treated mice cohorts (Figure 7A,B). However, Akt phosphoryla-
tion was significantly increased in the aortas from those mice receiving a single injection of trodusquemine (Figure
7A,C), without significant alterations in pS6 (Figure 7A,D). There were no differences in the expression levels of aor-
tic PTP1B in trodusquemine-treated mice when compared with the saline controls (Figure 7E), as expected, as the
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Figure 7. Global PTP1B inhibition improves aortic Akt signalling
(A) Western blot analysis of aortic tissues from saline, single dose and chronic HFD cohorts injected with insulin immediately prior to
culling. Quantification of p-IR (Tyr1162/1163) (B), p-Akt (Ser473) (C), p-S6 (Ser235/236) (D) and total PTP1B (E) using ImageJ software. Data are
represented as mean +− S.E.M. and analysed by one-way ANOVA followed by Dunnett’s t tests where *P≤0.05 when compared with saline
control.
inhibition of PTP1B with trodusquemine treatment has been shown to selectively inhibit PTP1B activity [19]. Inter-
estingly, there was also a significant increase in the aortic AMPKα1 phosphorylation and downstream p38 (Figure
8A–C respectively) in single-dose trodusquemine treated mouse aortas. Finally, previous research from our lab has
found deletion of hepatic PTP1B can improve the endoplasmic reticulum (ER) stress response [13,28], therefore, we
sought to determine the effect of trodusquemine treatment on markers of ER stress. There was no significant im-
provement in either inositol-requiring enzyme 1α (IRE1α) or in binding of immunoglobulin protein (BiP) across
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Figure 8. Global PTP1B inhibition improves aortic AMPK signalling
(A) Western blot analysis of aortic tissues from saline, single dose and chronic HFD cohorts injected with insulin immediately prior to culling.
Quantification, p-AMPKα (Thr172) (B) and p-p38 (Thr180/Tyr182) (C) using ImageJ software. Data are represented as mean +− S.E.M. and
analysed by one-way ANOVA followed by Dunnett’s t tests where *P≤0.05 when compared with saline control.
treatments (see Supplemetary Figure S2A–C). However, a single dose of trodusquemine had opposing effects, lead-
ing to increased phosphorylation of eukaryotic translation initiation factor 2a (eif2a) but a significant decrease in
the expression of C/EBP homologous protein (CHOP) (Supplementary Figure S2A,D,E). These data suggest that the
beneficial effects of PTP1B inhibition cannot be attributed to direct regulation of the IR itself, but instead involves an
Akt-AMPKα1-dependent mechanism.
Discussion
We demonstrate here, using the LDLR−/− mouse model of atherosclerosis, that pharmacological PTP1B systemic in-
hibition leads to protection against and reversal of atherosclerosis development, suggesting beneficial effects of PTP1B
inhibition for the treatment ofCVDs and reduction inCVD risk.We present evidence that, in addition to its improve-
ment in glucose homeostasis and adiposity, PTP1B inhibition results in activation of aortic Akt and AMPKα1, that
is independent of the effects on the IR itself. Most importantly, for the first time, we demonstrate that inhibition of
PTP1B results in a decrease in circulating serum cholesterol and triglyceride levels and protection against atheroscle-
rotic plaque formation.
Our findings complement our previous genetic research, where we demonstrated deletion of hepatic PTP1B pro-
tected against HFD-induced endothelial dysfunction, without altering body mass or adiposity [12]. However, in con-
trast with our original hypothesis, this was not a consequence of improvements in IR phosphorylation. Nonetheless,
these data are in agreement with several other studies from our lab, specifically both the liver inducible [28] and
the myeloid [14] PTP1B deletion models where, although exhibiting improved glucose homeostasis, did so inde-
pendently of the IR signalling cascade, suggestive of multiple targets for the beneficial effects of PTP1B inhibition.
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Likewise, PTP1B deletion within adipocytes was unable to improve IR signalling within this tissue [29]. Therefore,
this is suggestive that PTP1B inhibition, in addition to its anti-diabetic role,may also exert its actions through different
mechanism(s).
In the past few years, in support of our findings, there have been several studies supporting a beneficial role for
PTP1B in endothelial dysfunction that is independent of IR signalling but, instead, dependent on that of vascular
endothelial growth factor (VEGF) signalling through the negative regulation of VEGF receptor 2 (VEGFR2) (see
Thiebaut et al. [30] for a recent review). Pharmacological inhibition or genetic deletion of PTP1B improved heart
failure due to the beneficial effects on cardiac remodelling, such as increased contractile function, and a decrease
in cardiac hypertrophy in fibrosis [31]. A similar phenotype was observed in a model of sepsis, where whole-body
PTP1B deletion not only improved survival rate in response to septic shock, but decreased cardiac dysfunction and
the expression of pro-inflammatory markers such as IL1β, ICAM-1, VCAM-1, COX-2 and iNOS [32]. Furthermore,
a follow-up study where PTP1B was specifically deleted in endothelial cells, demonstrated again cardiac improve-
ment exhibiting increased survival after 20 weeks post-induction of heart failure [33]. Critically, these improvements
were accompanied by an increase in VEGFR signalling and angiogenesis. Finally, in a model of hind limb ischaemia,
deletion of PTP1B in endothelial cells led to angiogenesis and arteriogenesis both in vitro and in vivo, and was me-
diated by enhanced VEGFR signalling [34]. Therefore, the possibility that improved VEGFR signalling is involved
in the beneficial effects observed in trodusquemine treated mice, although not investigated during the present study,
cannot be ruled out and is worth future investigation. Likewise, the effect of trodusquemine treatment on additional
cell types not limited to the vasculature, such as those involved in the immune response must also be considered, as
trodusquemine acts as the global PTP1B inhibitor.
Nonetheless, importantly, we observed enhancement of aortic AMPK α1 phosphorylation in HFD-fed mice given
a single dose of trodusquemine. This is in agreement with a similar recent study in which the PTP1B global knockout
exhibited improved cardiomyocyte contractility inmice fed on HFD, through an AMPK-dependent mechanism [35].
In addition, an independent study using the LDLR−/− mouse model of atherosclerosis, found deletion of AMPKα1
specifically in the myeloid lineage, led to hypercholesterolemia, increased macrophage inflammation and plaque in-
filtration and exacerbated atherogenesis [36]. Therefore, the robust phosphorylation of aortic AMPKα1 observed in
response to a single injection, and to some extent, chronic global PTP1B inhibition with trodusquemine, and the
associated protection and reversal of atherosclerotic plaque area, suggest that PTP1B inhibition may be protective
through an AMPKα1-driven mechanism. It is important to note that at the time of culling, single dose and chronic
drug treated mice had 4- and 6-weeks washout of drug respectively. This 2-week difference may explain why chronic
treatment did not exhibit phosphorylation of AMPK α1 or Akt to the same extent as those given a single injection.
A group of mice receiving single or chronic trodusquemine with no washout period would be required to assess if
trodusquemine could directly lead to hyperphosphorylation of AMPKα1 and Akt. However, despite this, both drug
treated cohorts exhibited the same degree of decreased plaque formation.
Critically, atherosclerosis is nowwell regarded as a chronic low-level inflammatorydisease accompanied by a failure
to initiate anti-inflammatory signalling, thereby preventing successful engagement of pro-resolutionmechanisms and
a return to tissue homeostasis. In contrast with previous therapies, including those which inhibit pro-inflammatory
signalling, current research is focusing on the promotion from pro-inflammation to pro-resolution, as a means to
reduce atherosclerotic plaque development, as well as other chronic inflammatory pathologies [37,38]. Our study
revealed a decrease in MCP-1 expression in trodusquemine-treated mice, suggesting that PTP1B inhibition led to a
less pro-inflammatory environment. Furthermore, in our model where PTP1B deletion was myeloid specific, these
mice exhibited a decrease in pro-inflammatory IL-6 and TNFα, and an increase in pro-resolution IL-10 [14]. Fi-
nally, a recent study by Zhu et al. [39] found that IL-10 stimulation of AMPKα phosphorylation and subsequent
downstreamPI3K/Akt/mTORC1 signallingwas critical for eliciting the anti-inflammatory properties of this cytokine.
Therefore collectively, these data suggest that PTP1B inhibition may contribute in the switch from pro-inflammation
to pro-resolution signalling, via IL-10/AMPKαmechanism.
In conclusion, we demonstrate that global pharmacological inhibition of PTP1B, in addition to its anti-diabetic and
weight loss benefits, resulted in both the reduction and reversal in atherosclerotic plaque formation under obesogenic
conditions (as achieved by chronic and a single dose exposure, respectively). This was achieved via an IR-independent
pathway, and instead engaged Akt/AMPKα signalling to promote a decrease in pro-inflammatory environment.
Hence our data strongly suggest that PTP1B inhibitors may be used in pathologies other than type 2 diabetes and
that those currently in pre-clinical trials [20], could be repurposed to target chronic inflammatory pathologies, such
as atherosclerosis and help to reduce CVD risk.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
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Clinical perspectives
• CVD is the most prevalent cause of mortality among patients with type 1 or type 2 diabetes due to
accelerated atherosclerosis.
• Inhibiting the activity of PTP1B prevents and reverses atherosclerotic plaque formation in LDLR−/−
mousemodel of atherosclerosis, and is associated with a decrease in aortic MCP-1 expression levels,
hyperphosphorylation of aortic Akt/PKB and AMPKα.
• Our findings are the first to demonstrate that PTP1B inhibitors could be used in prevention and
reversal of atherosclerosis.
Acknowledgements
We thank Professor Nicholas Tonks for providing the PTP1B inhibitor trodusquemine; Linda Davidson for her help with the aorta
histology; Dr Fiona Greig for tuition into aortic dissection and Dr James Hislop for critical reading of this manuscript.
Author contribution
D.T. performed the experiments and wrote the manuscript. N.M. assisted with GTT experiments and terminal culls. L.G. performed
qPCR in Figure 6. N.M., S.L.M. and E.K.L. aided with terminal procedures. H.M.W. suggested experiments and reviewed the
manuscript. M.D. conceived and designed the experiments and wrote the manuscript.
Funding
This work was supported by the the British Heart Foundation [grant number PG/14/43/30889].
Competing interests
The authors declare that there are no competing interests associated with the manuscript.
Abbreviations
ApoE−/−, apolipoprotein-E-deficient mice; AMPK, AMP-activated kinase; C/EBP, CCAAT/enhancer binding protein; COX-2,
cyclooxegenase-2; CVD, cardiovascular disease; Elf1, E74-like factor 1; ER, endoplasmic reticulum; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; GTT, glucose tolerance test; HFD, high fat diet; ICAM-1, intracellular cell adhesion molecule-1; IL,
interleukin; iNOS, inducible nitric oxide synthase; IR, insulin receptor; IRS1, IR substrate 1; I.P., intraperitoneally; LDLR−/−, low
density lipoprotein receptor deficient mice; mTORC1, mammalian target of rapamycin complex 1; MCP-1, monocyte chemoat-
tractant protein-1; PI3K, phosphoinositide 3-kinase; PKB, protein kinase B; PTP1B, protein tyrosine phosphatase 1B; TNFα,
tumor necrosis factor α; VCAM-1, vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; VEGFR, VEGF
receptor; WHO, World Health Organization.
References
1 Libby, P. (2012) Inﬂammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32, 2045–2051
2 Badimon, L. and Vilahur, G. (2014) Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med. 276, 618–632
3 Moon, B.C., Hernandez-Ono, A., Stiles, B., Wu, H. and Ginsberg, H.N. (2012) Apolipoprotein B secretion is regulated by hepatic triglyceride, and not
insulin, in a model of increased hepatic insulin signaling. Arterioscler. Thromb. Vasc. Biol. 32, 236–246
4 Matheus, A.S., Tannus, L.R., Cobas, R.A., Palma, C.C., Negrato, C.A. and Gomes, M.B. (2013) Impact of diabetes on cardiovascular disease: an update.
Int. J. Hypertens. 2013, 653789
5 Rask-Madsen, C., Li, Q., Freund, B., Feather, D., Abramov, R., Wu, I.H. et al. (2010) Loss of insulin signaling in vascular endothelial cells accelerates
atherosclerosis in apolipoprotein E null mice. Cell Metab. 11, 379–389
6 Galkina, E.V., Butcher, M., Keller, S.R., Goff, M., Bruce, A., Pei, H. et al. (2012) Accelerated atherosclerosis in Apoe-/- mice heterozygous for the insulin
receptor and the insulin receptor substrate-1. Arterioscler. Thromb. Vasc. Biol. 32, 247–256
7 Baumgartl, J., Baudler, S., Scherner, M., Babaev, V., Makowski, L., Suttles, J. et al. (2006) Myeloid lineage cell-restricted insulin resistance protects
apolipoproteinE-deﬁcient mice against atherosclerosis. Cell Metab. 3, 247–256
8 Rensing, K.L., de Jager, S.C., Stroes, E.S., Vos, M., Twickler, M.T., Dallinga-Thie, G.M. et al. (2014) Akt2/LDLr double knockout mice display impaired
glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout mice. Cardiovasc. Res. 101, 277–287
9 Delibegovic, M. and Mody, N. (2013) PTP1B in the periphery: regulating insulin sensitivity and ER stress. In Protein Tyrosine Phosphatase Control of
Metabolism (Bence, K.K., ed.), pp. 91–105, Springer New York, New York, NY
2500 c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY).
Clinical Science (2017) 131 2489–2501
DOI: 10.1042/CS20171066
10 Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, A.L. et al. (1999) Increased insulin sensitivity and obesity resistance in mice
lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544–1548
11 Klaman, L.D., Boss, O., Peroni, O.D., Kim, J.K., Martino, J.L., Zabolotny, J.M. et al. (2000) Increased energy expenditure, decreased adiposity, and
tissue-speciﬁc insulin sensitivity in protein-tyrosine phosphatase 1B-deﬁcient mice. Mol. Cell. Biol. 20, 5479–5489
12 Agouni, A., Tual-Chalot, S., Chalopin, M., Duluc, L., Mody, N., Martinez, M.C. et al. (2014) Hepatic protein tyrosine phosphatase 1B (PTP1B) deﬁciency
protects against obesity-induced endothelial dysfunction. Biochem. Pharmacol. 92, 607–617
13 Agouni, A., Mody, N., Owen, C., Czopek, A., Zimmer, D., Bentires-Alj, M. et al. (2011) Liver-speciﬁc deletion of protein tyrosine phosphatase (PTP) 1B
improves obesity- and pharmacologically induced endoplasmic reticulum stress. Biochem. J. 438, 369–378
14 Grant, L., Shearer, K.D., Czopek, A., Lees, E.K., Owen, C., Agouni, A. et al. (2014) Myeloid-cell protein tyrosine phosphatase-1B deﬁciency in mice
protects against high-fat diet and lipopolysaccharide-induced inﬂammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent
mechanism. Diabetes 63, 456–470
15 Liang, C.P., Han, S., Senokuchi, T. and Tall, A.R. (2007) The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ. Res. 100,
1546–1555
16 Lackey, D.E. and Olefsky, J.M. (2016) Regulation of metabolism by the innate immune system. Nat. Rev. Endocrinol. 12, 15–28
17 Tabas, I. and Bornfeldt, K.E. (2016) Macrophage phenotype and function in different stages of atherosclerosis. Circ. Res. 118, 653–667
18 Rocha, V.Z. and Libby, P. (2009) Obesity, inﬂammation, and atherosclerosis. Nat. Rev. Cardiol. 6, 399–409
19 Lantz, K.A., Hart, S.G., Planey, S.L., Roitman, M.F., Ruiz-White, I.A., Wolfe, H.R. et al. (2010) Inhibition of PTP1B by trodusquemine (MSI-1436) causes
fat-speciﬁc weight loss in diet-induced obese mice. Obesity (Silver Spring) 18, 1516–1523
20 Tamrakar, A.K., Maurya, C.K. and Rai, A.K. (2014) PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 – 2014). Expert Opin. Ther. Pat.
24, 1101–1115
21 Ishibashi, S., Brown, M.S., Goldstein, J.L., Gerard, R.D., Hammer, R.E. and Herz, J. (1993) Hypercholesterolemia in low density lipoprotein receptor
knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883–893
22 Krishnan, N., Koveal, D., Miller, D.H., Xue, B., Akshinthala, S.D., Kragelj, J. et al. (2014) Targeting the disordered C terminus of PTP1B with an allosteric
inhibitor. Nat. Chem. Biol. 10, 558–566
23 Surwit, R.S., Kuhn, C.M., Cochrane, C., McCubbin, J.A. and Feinglos, M.N. (1988) Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37,
1163–1167
24 Montgomery, M.K., Hallahan, N.L., Brown, S.H., Liu, M., Mitchell, T.W., Cooney, G.J. et al. (2013) Mouse strain-dependent variation in obesity and
glucose homeostasis in response to high-fat feeding. Diabetologia 56, 1129–1139
25 Lacey, B., Herrington, W.G., Preiss, D., Lewington, S. and Armitage, J. (2017) The role of emerging risk factors in cardiovascular outcomes. Curr.
Atheroscler. Rep. 19, 28
26 Fredman, G. and Tabas, I. (2017) Boosting inﬂammation resolution in atherosclerosis: the next frontier for therapy. Am. J. Pathol. 187, 1211–1221
27 Heinz, J., Marinello, M. and Fredman, G. (2017) Pro-resolution therapeutics for cardiovascular diseases. Prostaglandins Other Lipid Mediat.,
doi:10.1016/j.prostaglandins.2017.03.004
28 Owen, C., Lees, E.K., Grant, L., Zimmer, D.J., Mody, N., Bence, K.K. et al. (2013) Inducible liver-speciﬁc knockdown of protein tyrosine phosphatase 1B
improves glucose and lipid homeostasis in adult mice. Diabetologia 56, 2286–2296
29 Owen, C., Czopek, A., Agouni, A., Grant, L., Judson, R., Lees, E.K. et al. (2012) Adipocyte-speciﬁc protein tyrosine phosphatase 1B deletion increases
lipogenesis, adipocyte cell size and is a minor regulator of glucose homeostasis. PLoS ONE 7, e32700
30 Thiebaut, P.A., Besnier, M., Gomez, E. and Richard, V. (2016) Role of protein tyrosine phosphatase 1B in cardiovascular diseases. J. Mol. Cell. Cardiol.
101, 50–57
31 Gomez, E., Vercauteren, M., Kurtz, B., Ouvrard-Pascaud, A., Mulder, P., Henry, J.P. et al. (2012) Reduction of heart failure by pharmacological inhibition
or gene deletion of protein tyrosine phosphatase 1B. J. Mol. Cell. Cardiol. 52, 1257–1264
32 Coquerel, D., Neviere, R., Delile, E., Mulder, P., Marechal, X., Montaigne, D. et al. (2014) Gene deletion of protein tyrosine phosphatase 1B protects
against sepsis-induced cardiovascular dysfunction and mortality. Arterioscler. Thromb. Vasc. Biol. 34, 1032–1044
33 Gogiraju, R., Schroeter, M.R., Bochenek, M.L., Hubert, A., Munzel, T., Hasenfuss, G. et al. (2016) Endothelial deletion of protein tyrosine phosphatase-1B
protects against pressure overload-induced heart failure in mice. Cardiovasc. Res. 111, 204–216
34 Lanahan, A.A., Lech, D., Dubrac, A., Zhang, J., Zhuang, Z.W., Eichmann, A. et al. (2014) PTP1b is a physiologic regulator of vascular endothelial growth
factor signaling in endothelial cells. Circulation 130, 902–909
35 Kandadi, M.R., Panzhinskiy, E., Roe, N.D., Nair, S., Hu, D. and Sun, A. (2015) Deletion of protein tyrosine phosphatase 1B rescues against myocardial
anomalies in high fat diet-induced obesity: Role of AMPK-dependent autophagy. Biochim. Biophys. Acta 1852, 299–309
36 Cao, Q., Cui, X., Wu, R., Zha, L., Wang, X., Parks, J.S. et al. (2016) Myeloid deletion of α1AMPK exacerbates atherosclerosis in LDL receptor knockout
(LDLRKO) mice. Diabetes 65, 1565–1576
37 Lameijer, M.A., Tang, J., Nahrendorf, M., Beelen, R.H. and Mulder, W.J. (2013) Monocytes and macrophages as nanomedicinal targets for improved
diagnosis and treatment of disease. Expert Rev. Mol. Diagn. 13, 567–580
38 Han, X. and Boisvert, W.A. (2015) Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function. Thromb.
Haemost. 113, 505–512
39 Zhu, Y.P., Brown, J.R., Sag, D., Zhang, L. and Suttles, J. (2015) Adenosine 5′-monophosphate-activated protein kinase regulates IL-10-mediated
anti-inﬂammatory signaling pathways in macrophages. J. Immunol. 194, 584–594
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY).
2501
